share_log

EF Hutton Maintains Buy on Pasithea Therapeutics, Lowers Price Target to $2

EF Hutton Maintains Buy on Pasithea Therapeutics, Lowers Price Target to $2

EF Hutton 维持对Pasithea Therapeutics的买入,将目标价下调至2美元
Benzinga ·  2023/04/03 10:01

EF Hutton analyst Constantine Davides maintains Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and lowers the price target from $2.3 to $2.

EF Hutton分析师康斯坦丁·戴维斯维持Pasithea Therapeutics(纳斯达克股票代码:KTTA)的买入,并将目标股价从2.3美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发